FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462936585> ?p ?o ?g. }

• W2462936585 endingPage "1882" @default.
• W2462936585 startingPage "1874" @default.
• W2462936585 abstract "Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable and potentially fatal complication of hematopoietic cell transplantation (HCT) or nontransplantation-associated chemotherapy/radiotherapy. In cases of severe hepatic VOD/SOS, typically defined by associated multiorgan failure (MOF, also known as multiorgan dysfunction), mortality exceeds 80%. Preclinical and early clinical data have provided a rationale for defibrotide treatment in hepatic VOD/SOS. Based on this evidence and in recognition of the dismal prognosis for these patients, defibrotide was made available through an international multicenter compassionate-use program conducted from December 1998 to March 2009. Physicians participating in the program voluntarily provided demographic and outcome data for patients given defibrotide. Efficacy and safety analyses were performed using the data received for 710 treated patients. Defibrotide was given at 10, 25, 40, 60, or 80 mg/kg/day for a median of 15 days (range, 1 to 119 days). By Kaplan-Meier analysis, the estimated overall day +100 survival was 54% (58% in the 25 mg/kg/day dose group). Adverse events (AEs) were reported in 53% of patients. The most common AEs were MOF, progression of hepatic VOD/SOS, sepsis, and graft-versus-host disease, which were consistent with the AEs expected for this patient population. No clinically meaningful trends in AEs were identified by gender, age, or dose group. Safety and efficacy resultswere consistent with prior studies of defibrotide in hepatic VOD/SOS, and subgroup analyses lend support to the use of the 25 mg/kg/day dose." @default.
• W2462936585 created "2016-07-22" @default.
• W2462936585 creator A5001390394 @default.
• W2462936585 creator A5001754709 @default.
• W2462936585 creator A5003455280 @default.
• W2462936585 creator A5020996390 @default.
• W2462936585 creator A5022882979 @default.
• W2462936585 creator A5027302651 @default.
• W2462936585 creator A5029260153 @default.
• W2462936585 creator A5033775906 @default.
• W2462936585 creator A5041128935 @default.
• W2462936585 creator A5042734609 @default.
• W2462936585 creator A5043526996 @default.
• W2462936585 creator A5062422990 @default.
• W2462936585 creator A5070993902 @default.
• W2462936585 creator A5074031750 @default.
• W2462936585 creator A5078683084 @default.
• W2462936585 creator A5081252933 @default.
• W2462936585 creator A5087561645 @default.
• W2462936585 date "2016-10-01" @default.
• W2462936585 modified "2023-10-18" @default.
• W2462936585 title "Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program" @default.
• W2462936585 cites W143372461 @default.
• W2462936585 cites W1966771497 @default.
• W2462936585 cites W1972172571 @default.
• W2462936585 cites W1973519172 @default.
• W2462936585 cites W1989547955 @default.
• W2462936585 cites W1993783426 @default.
• W2462936585 cites W199387403 @default.
• W2462936585 cites W1996485480 @default.
• W2462936585 cites W2012187988 @default.
• W2462936585 cites W2032544348 @default.
• W2462936585 cites W2035518655 @default.
• W2462936585 cites W2037010003 @default.
• W2462936585 cites W2061293556 @default.
• W2462936585 cites W2064322221 @default.
• W2462936585 cites W2066216766 @default.
• W2462936585 cites W2067329870 @default.
• W2462936585 cites W2077086197 @default.
• W2462936585 cites W2079829835 @default.
• W2462936585 cites W2087647234 @default.
• W2462936585 cites W2121599032 @default.
• W2462936585 cites W2125312770 @default.
• W2462936585 cites W2148164607 @default.
• W2462936585 cites W2151348405 @default.
• W2462936585 cites W2295805773 @default.
• W2462936585 cites W2418948359 @default.
• W2462936585 cites W2980045661 @default.
• W2462936585 cites W4252620072 @default.
• W2462936585 doi "https://doi.org/10.1016/j.bbmt.2016.07.001" @default.
• W2462936585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27397724" @default.
• W2462936585 hasPublicationYear "2016" @default.
• W2462936585 type Work @default.
• W2462936585 sameAs 2462936585 @default.
• W2462936585 citedByCount "72" @default.
• W2462936585 countsByYear W24629365852016 @default.
• W2462936585 countsByYear W24629365852017 @default.
• W2462936585 countsByYear W24629365852018 @default.
• W2462936585 countsByYear W24629365852019 @default.
• W2462936585 countsByYear W24629365852020 @default.
• W2462936585 countsByYear W24629365852021 @default.
• W2462936585 countsByYear W24629365852022 @default.
• W2462936585 countsByYear W24629365852023 @default.
• W2462936585 crossrefType "journal-article" @default.
• W2462936585 hasAuthorship W2462936585A5001390394 @default.
• W2462936585 hasAuthorship W2462936585A5001754709 @default.
• W2462936585 hasAuthorship W2462936585A5003455280 @default.
• W2462936585 hasAuthorship W2462936585A5020996390 @default.
• W2462936585 hasAuthorship W2462936585A5022882979 @default.
• W2462936585 hasAuthorship W2462936585A5027302651 @default.
• W2462936585 hasAuthorship W2462936585A5029260153 @default.
• W2462936585 hasAuthorship W2462936585A5033775906 @default.
• W2462936585 hasAuthorship W2462936585A5041128935 @default.
• W2462936585 hasAuthorship W2462936585A5042734609 @default.
• W2462936585 hasAuthorship W2462936585A5043526996 @default.
• W2462936585 hasAuthorship W2462936585A5062422990 @default.
• W2462936585 hasAuthorship W2462936585A5070993902 @default.
• W2462936585 hasAuthorship W2462936585A5074031750 @default.
• W2462936585 hasAuthorship W2462936585A5078683084 @default.
• W2462936585 hasAuthorship W2462936585A5081252933 @default.
• W2462936585 hasAuthorship W2462936585A5087561645 @default.
• W2462936585 hasBestOaLocation W24629365851 @default.
• W2462936585 hasConcept C126322002 @default.
• W2462936585 hasConcept C141071460 @default.
• W2462936585 hasConcept C197934379 @default.
• W2462936585 hasConcept C2775832928 @default.
• W2462936585 hasConcept C2777408962 @default.
• W2462936585 hasConcept C2777712501 @default.
• W2462936585 hasConcept C2778384902 @default.
• W2462936585 hasConcept C2780895475 @default.
• W2462936585 hasConcept C2908647359 @default.
• W2462936585 hasConcept C2911091166 @default.
• W2462936585 hasConcept C71924100 @default.
• W2462936585 hasConcept C81182388 @default.
• W2462936585 hasConcept C99454951 @default.
• W2462936585 hasConceptScore W2462936585C126322002 @default.
• W2462936585 hasConceptScore W2462936585C141071460 @default.
• W2462936585 hasConceptScore W2462936585C197934379 @default.

• next